Search

Your search keyword '"MESH: Off-Label Use"' showing total 2 results
Start Over Descriptor "MESH: Off-Label Use" Language undetermined
2 results on '"MESH: Off-Label Use"'

1. Emerging cardiovascular indications of mineralocorticoid receptor antagonists

Author

Yasir Parviz, Abdallah Al-Mohammad, Faiez Zannad, David Adlam, Javaid Iqbal, Bertram Pitt, Sheffield Teaching Hospitals National Health Service Foundation Trust, Manchester Heart Centre, Manchester Royal Infirmary, University of Michigan [Ann Arbor], University of Michigan System, Glenfield Hospital, Centre d'investigation clinique [Nancy] (CIC), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Cardiologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), and Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)

Subjects
Endocrinology, Diabetes and Metabolism, Severity of Illness Index, Sudden cardiac death, Coronary artery disease, chemistry.chemical_compound, Endocrinology, Mineralocorticoid receptor, MESH: Receptors, Mineralocorticoid, MESH: Animals, Mineralocorticoid Receptor Antagonists, valvular heart disease, 3. Good health, Eplerenone, MESH: Arrhythmias, Cardiac, spironolactone, Cardiovascular Diseases, Cardiology, Disease Progression, MESH: Disease Progression, MESH: Cardiovascular Agents, medicine.drug, medicine.medical_specialty, Hypertension, Pulmonary, MESH: Mineralocorticoid Receptor Antagonists, Models, Biological, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, MESH: Severity of Illness Index, medicine, MESH: Off-Label Use, Animals, Humans, eplerenone, mineralocorticoid receptor, Heart Failure, MESH: Humans, MESH: Hypertension, Pulmonary, business.industry, MESH: Models, Biological, MESH: Cardiovascular Diseases, MESH: Death, Sudden, Cardiac, Arrhythmias, Cardiac, Cardiovascular Agents, novel indications, Off-Label Use, medicine.disease, Death, Sudden, Cardiac, Receptors, Mineralocorticoid, chemistry, Heart failure, MESH: Heart Failure, Spironolactone, business, Heart failure with preserved ejection fraction
Abstract

International audience; Mineralocorticoid receptor (MR) antagonism is a well-established treatment modality for patients with hypertension, heart failure, and left ventricular systolic dysfunction (LVSD) post-myocardial infarction (MI). There are emerging data showing potential benefits of MR antagonists in other cardiovascular conditions. Studies have shown association between MR activation and the development of myocardial fibrosis, coronary artery disease, metabolic syndrome, and cerebrovascular diseases. This review examines the preclinical and clinical data of MR antagonists for novel indications including heart failure with preserved ejection fraction (HFPEF), pulmonary arterial hypertension (PAH), arrhythmia, sudden cardiac death, valvular heart disease, metabolic syndrome, renal disease, and stroke. MR antagonists are not licensed for these conditions yet; however, emerging data suggest that indication for MR antagonists are likely to broaden; further studies are warranted.

Published
2014
Full Text
View/download PDF

2. Death of an alcohol-dependent patient following intentional drug intoxication: implication of baclofen?

Author

Lucie Javot, Emilie Roman, Carine Thivilier, Julien Scala-Bertola, Nicolas Gambier, Elise Pape, Jean-Yves Jouzeau, Franck Saint-Marcoux, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service de Pharmacologie, toxicologie et pharmacovigilance [CHU Limoges], and CHU Limoges

Subjects
Male, MESH: Fatal Outcome, Baclofen, Health (social science), Medicine (miscellaneous), Off-label use, chemistry.chemical_compound, Fatal Outcome, MESH: Middle Aged, musculoskeletal, neural, and ocular physiology, Middle Aged, 3. Good health, MESH: Baclofen, Psychiatry and Mental health, Alcoholism, Anesthesia, medicine.symptom, MESH: Ethanol, Context (language use), Drug overdose, MESH: Trimeprazine, MESH: Alcoholism, medicine, MESH: Off-Label Use, Humans, Spasticity, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], Medical prescription, MESH: Humans, Ethanol, business.industry, organic chemicals, Alcohol dependence, Central Nervous System Depressants, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, Antipruritics, Off-Label Use, Trimeprazine, medicine.disease, MESH: Male, MESH: GABA-B Receptor Agonists, body regions, nervous system, chemistry, Concomitant, GABA-B Receptor Agonists, MESH: Antipruritics, MESH: Drug Overdose, MESH: Central Nervous System Depressants, Drug Overdose, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Used in the treatment of spasticity at low doses, baclofen is also prescribed off-label at high doses for the treatment of alcohol dependence. Several cases of baclofen intoxication have been reported, but only 1 case deals with the treatment of alcohol dependence. Thus, we report the first death in the context of baclofen off-label use of an alcohol-dependent patient with a high blood baclofen concentration after intentional drug intoxication. The safety profile of baclofen in the treatment of alcohol dependence is reviewed and discussed, underlining the obligatory caution that may support any prescription of high doses of baclofen in this off-label indication and especially in patients with concomitant psychiatric disorders.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results